PortalPublikationenMAGE-A gene expression pattern in primary breast cancer.

MAGE-A gene expression pattern in primary breast cancer.

Standard

MAGE-A gene expression pattern in primary breast cancer. / Otte, M; Zafrakas, M; Riethdorf, L; Pichlmeier, U; Löning, Thomas; Jänicke, F; Pantel, K.

in: CANCER RES, Jahrgang 61, Nr. 18, 18, 2001, S. 6682-6687.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Otte, M, Zafrakas, M, Riethdorf, L, Pichlmeier, U, Löning, T, Jänicke, F & Pantel, K 2001, 'MAGE-A gene expression pattern in primary breast cancer.', CANCER RES, Jg. 61, Nr. 18, 18, S. 6682-6687. <http://www.ncbi.nlm.nih.gov/pubmed/11559535?dopt=Citation>

APA

Otte, M., Zafrakas, M., Riethdorf, L., Pichlmeier, U., Löning, T., Jänicke, F., & Pantel, K. (2001). MAGE-A gene expression pattern in primary breast cancer. CANCER RES, 61(18), 6682-6687. [18]. http://www.ncbi.nlm.nih.gov/pubmed/11559535?dopt=Citation

Vancouver

Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F et al. MAGE-A gene expression pattern in primary breast cancer. CANCER RES. 2001;61(18):6682-6687. 18.

Bibtex

@article{6b60e23b179c48c9987288ba78c1ab48,
title = "MAGE-A gene expression pattern in primary breast cancer.",
abstract = "Melanoma antigen (MAGE)-A-derived peptides elicit a strong in vitro T-cell response against tumor cells. For determination of MAGE-A1, -2, -3, -4, -6, and -12 expression profile in invasive breast cancer, we developed a multiplex seminested reverse transcription-PCR-method. In total, 18 of 67 (27%) tumors were positive for at least one of these MAGE transcripts, and the expression pattern was heterogeneous: MAGE-A1 was positive in 4 of 67 (6%), MAGE-A2 in 13 of 67 (19%), MAGE-A3 in 7 of 67 (10%), MAGE-A4 in 9 of 67 (13%), MAGE-A6 in 10 of 67 (15%), and MAGE-A12 in 6 of 67 (9%) patients. The MAGE-A transcripts were more frequently expressed in ductal breast carcinomas compared with other histomorphological types. We observed a preferential expression of MAGE-A in patients at a higher risk of recurrence: those harboring tumors with high levels of the protease urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor 1, high score of the Ki-67 proliferation antigen, and lesser degree of differentiation. Our findings suggests a potential involvement of MAGE-A in tumor progression, with potential implications for active immunotherapy.",
author = "M Otte and M Zafrakas and L Riethdorf and U Pichlmeier and Thomas L{\"o}ning and F J{\"a}nicke and K Pantel",
year = "2001",
language = "Deutsch",
volume = "61",
pages = "6682--6687",
journal = "CANCER RES",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

RIS

TY - JOUR

T1 - MAGE-A gene expression pattern in primary breast cancer.

AU - Otte, M

AU - Zafrakas, M

AU - Riethdorf, L

AU - Pichlmeier, U

AU - Löning, Thomas

AU - Jänicke, F

AU - Pantel, K

PY - 2001

Y1 - 2001

N2 - Melanoma antigen (MAGE)-A-derived peptides elicit a strong in vitro T-cell response against tumor cells. For determination of MAGE-A1, -2, -3, -4, -6, and -12 expression profile in invasive breast cancer, we developed a multiplex seminested reverse transcription-PCR-method. In total, 18 of 67 (27%) tumors were positive for at least one of these MAGE transcripts, and the expression pattern was heterogeneous: MAGE-A1 was positive in 4 of 67 (6%), MAGE-A2 in 13 of 67 (19%), MAGE-A3 in 7 of 67 (10%), MAGE-A4 in 9 of 67 (13%), MAGE-A6 in 10 of 67 (15%), and MAGE-A12 in 6 of 67 (9%) patients. The MAGE-A transcripts were more frequently expressed in ductal breast carcinomas compared with other histomorphological types. We observed a preferential expression of MAGE-A in patients at a higher risk of recurrence: those harboring tumors with high levels of the protease urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor 1, high score of the Ki-67 proliferation antigen, and lesser degree of differentiation. Our findings suggests a potential involvement of MAGE-A in tumor progression, with potential implications for active immunotherapy.

AB - Melanoma antigen (MAGE)-A-derived peptides elicit a strong in vitro T-cell response against tumor cells. For determination of MAGE-A1, -2, -3, -4, -6, and -12 expression profile in invasive breast cancer, we developed a multiplex seminested reverse transcription-PCR-method. In total, 18 of 67 (27%) tumors were positive for at least one of these MAGE transcripts, and the expression pattern was heterogeneous: MAGE-A1 was positive in 4 of 67 (6%), MAGE-A2 in 13 of 67 (19%), MAGE-A3 in 7 of 67 (10%), MAGE-A4 in 9 of 67 (13%), MAGE-A6 in 10 of 67 (15%), and MAGE-A12 in 6 of 67 (9%) patients. The MAGE-A transcripts were more frequently expressed in ductal breast carcinomas compared with other histomorphological types. We observed a preferential expression of MAGE-A in patients at a higher risk of recurrence: those harboring tumors with high levels of the protease urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor 1, high score of the Ki-67 proliferation antigen, and lesser degree of differentiation. Our findings suggests a potential involvement of MAGE-A in tumor progression, with potential implications for active immunotherapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 61

SP - 6682

EP - 6687

JO - CANCER RES

JF - CANCER RES

SN - 0008-5472

IS - 18

M1 - 18

ER -